MMT 205
Alternative Names: MMT-205; MT-103- CURACLELatest Information Update: 30 Jun 2026
At a glance
- Originator CURACLE
- Developer CURACLE; Memento Medicines
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action Angiopoietin-2 inhibitors; TIE-2 receptor agonists; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Retinal disorders; Wet age-related macular degeneration